A Cross-Sectional Study of Exposure Factors Associated with Seropositivity for SARS-CoV-2 Antibodies during the Second Epidemic Wave among a Sample of the University of Corsica (France).


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
10 02 2022
Historique:
received: 05 01 2022
revised: 03 02 2022
accepted: 07 02 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 3 3 2022
Statut: epublish

Résumé

This study aimed to estimate the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection within the staff and student populations of the University of Corsica (France) during the second wave of the epidemic. A cross-sectional survey was conducted from 23 November 2020 to 31 January 2021. The participants underwent blood sampling using a fingerstick procedure and completed an anonymized questionnaire. Sera were tested for the presence of anti-SARS-CoV-2 IgG (ELISA-S) and, if positive, with an in-house virus neutralization test (VNT). A total of 418 persons were included in the study. The overall seroprevalence was 12.8% (95% confidence interval (CI), 9.8-16.6%). A total of 15 (31%) of the 49 individuals who had a positive ELISA-S also had a positive VNT. Seropositivity was associated with living at the city campus during the week and on weekends (OR = 3.74 [1.40-12.00]), using public transportation/carpooling (OR = 2.00 [1.01-4.02]), and being in contact with a person who tested positive for SARS-CoV-2 (OR = 2.32 [1.20-4.40]). The main symptoms associated with seropositivity were "having had an acute respiratory infection" (OR = 3.05 [1.43-6.43]) and "experiencing loss of smell" (OR = 16.4 [5.87-50.7]). These results could be useful for SARS-CoV-2 prevention and control on university campuses.

Identifiants

pubmed: 35206161
pii: ijerph19041953
doi: 10.3390/ijerph19041953
pmc: PMC8872171
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
EXCLI J. 2021 Feb 09;20:276-280
pubmed: 33628163
JAMA. 2020 Jun 2;323(21):2137-2138
pubmed: 32239184
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Emerg Microbes Infect. 2020 Dec;9(1):2509-2514
pubmed: 33238813
Int J Environ Res Public Health. 2021 Sep 22;18(19):
pubmed: 34639273
J Adolesc Health. 2020 Dec;67(6):763-768
pubmed: 33071164
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
BMC Public Health. 2021 Sep 19;21(1):1704
pubmed: 34538240
J Infect. 2021 Jul;83(1):104-111
pubmed: 33933527
Antiviral Res. 2020 Sep;181:104880
pubmed: 32679056
Life (Basel). 2020 Sep 21;10(9):
pubmed: 32967110
Front Public Health. 2021 Jul 26;9:715192
pubmed: 34381756
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
J Clin Med. 2020 Nov 05;9(11):
pubmed: 33167563
J Med Internet Res. 2020 Oct 12;22(10):e19994
pubmed: 33001833
JMIR Public Health Surveill. 2021 Jan 11;7(1):e24320
pubmed: 33315576
Auris Nasus Larynx. 2020 Aug;47(4):565-573
pubmed: 32553562
Int J Environ Res Public Health. 2021 Feb 16;18(4):
pubmed: 33669412
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Int J Hyg Environ Health. 2020 Sep;230:113610
pubmed: 32896785
Lancet Reg Health Eur. 2021 Aug;7:100148
pubmed: 34124709
Trop Med Int Health. 2009 Nov;14 Suppl 1:14-20
pubmed: 19508436
Nat Commun. 2020 May 29;11(1):2800
pubmed: 32472043

Auteurs

Dorine Decarreaux (D)

Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.
INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, 75012 Paris, France.
Unité des Virus Émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.

Julie Sevila (J)

Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.

Shirley Masse (S)

Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.

Lisandru Capai (L)

Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.

Toscane Fourié (T)

Unité des Virus Émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.

Paola Mariela Saba Villarroel (PM)

Unité des Virus Émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.

Abdennour Amroun (A)

Unité des Virus Émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.

Elif Nurtop (E)

Unité des Virus Émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.

Matthieu Vareille (M)

Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.

Marie Pouquet (M)

INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, 75012 Paris, France.

Thierry Blanchon (T)

INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, 75012 Paris, France.

Xavier de Lamballerie (X)

Unité des Virus Émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.

Rémi Charrel (R)

Unité des Virus Émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France.

Alessandra Falchi (A)

Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH